SystImmune Inc Announces Appointment of Martín Sebastia

REDMOND, Wash., Feb. 10, 2022 /PRNewswire/ -- SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies, and...

Related Keywords

China , Chengdu , Sichuan , Canada , Buenos Aires , Distrito Federal , Argentina , El Salvador , Salvador , Yi Zhu , Martin Sebastian Olivo , School Of Medicine , While Systimmune Inc , Austral University In Buenos Aires , Eisai Inc , University Of Buenos Aires , Prnewswire Systimmune Inc , Biokin Pharmaceutical Co Ltd , Systimmune Inc , Immunomedics Inc , Securities Exchange , Protara Therapeutics Inc , Pharmacological Research , Clinical Development At Gilead Sciences Inc , University Of Salvador , Chief Medical Officer , Protara Therapeutics , Chief Executive Officer , Vice President , Clinical Development , Gilead Sciences , Global Clinical , Daiichi Sankyo Cancer Enterprise , Austral University , Clinical Oncologist , Enrique Torn , National Cancer Institute , Canada Clinical Trials , Redmond Washington , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Investigational New Drug , ,